Price Alert

Sarepta Therapeutics Inc. (SRPT)

NASDAQ: SRPT · Real-Time Price · USD

20.29

-0.01 (-0.05%)

At close: Aug 15, 2025, 10:18 AM

-0.05% (1D)

Bid	20.29
Market Cap	1.98B
Revenue (ttm)	2.48B
Net Income (ttm)	-57.96M
EPS (ttm)	-0.68
PE Ratio (ttm)	-29.84
Forward PE	8.51
Analyst	Hold

Ask	20.3
Volume	1,141,255
Avg. Volume (20D)	11,679,172
Open	20.43
Previous Close	20.30
Day's Range	19.89 - 20.47
52-Week Range	10.42 - 144.22
Beta	0.46

About SRPT

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol SRPT

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for SRPT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Sarepta Therapeutics has released their quartely earnings on Aug 6, 2025:

Revenue of $611.09M exceeds estimates by $80.65M, with 68.38% YoY growth.

EPS of 2.02 exceeds estimates by 1.01, with 369.77% YoY growth.

Next Earnings Release

Sarepta Therapeutics Inc. is scheduled to release its earnings on Nov 5, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 weeks ago

+5.81%

Shares of several biotechnology stocks are trading... Unlock content with Pro Subscription

2 weeks ago

+5.81%

Sarepta Therapeutics shares are trading higher after Barclays upgraded the stock from Underweight to Equal-Weight and raised its price target from $10 to $22.

News

15 hours ago · zacks.com

Sarepta Sells Arrowhead Stake to Fund Milestone Payment

Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.

2 days ago · businesswire.com

Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has sold 9,265,312 shares of common sto...

3 days ago · marketbeat.com

Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside

For Sarepta Therapeutics NASDAQ: SRPT, 2025 has been nothing short of an unmitigated disaster. The firm owns the only Food and Drug Administration (FDA)-approved gene therapy for the treatment of Duch...

3 days ago · barrons.com

These Stocks Are Moving the Most Today: Coinbase, MicroStrategy, Sarepta, Nvidia, AMD, and More

Coinbase and MicroStrategy stocks rose as Bitcoin price surged. Shares of Sarepta, Nvidia and AMD were falling in early trading Monday.

1 week ago · zacks.com

Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries

SRPT rallies after Q2 earnings and revenue beat expectations as Elevidys deliveries resume following FDA clearance.

1 week ago · zacks.com

Sarepta Therapeutics (SRPT) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Sarepta Therapeutics (SRPT) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with ...

1 week ago · zacks.com

Sarepta Therapeutics (SRPT) Tops Q2 Earnings and Revenue Estimates

Sarepta Therapeutics (SRPT) came out with quarterly earnings of $2.02 per share, beating the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $0.07 per share a year ago.

1 week ago · businesswire.com

Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2025...

1 week ago · zacks.com

Sarepta to Report Q2 Earnings: What's in Store for the Stock?

SRPT's Q2 report, set to arrive Aug. 6, is likely to have Elevidys updates, restructuring plans and sales outlook in sharp investor focus.

2 weeks ago · businesswire.com

Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2025 financial results after the Nas...

Load More News